Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways

被引：26

作者：

Garcia-Echeverria, Carlos ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, CH-4002 Basel, Switzerland

来源：

PURINERGIC SIGNALLING | 2009年 / 5卷 / 01期

关键词：

Cancer; Drug design; Kinase; MEK; PI3K; Raf; Targeted therapy; GROWTH-FACTOR RECEPTOR; PHOSPHOINOSITIDE; 3-KINASE; MAP KINASE; B-RAF; ANTITUMOR-ACTIVITY; SUPPRESSES GROWTH; CELL LUNG; CANCER; MEK; MUTATIONS;

D O I：

10.1007/s11302-008-9111-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

The identification and characterization of the components of individual signal transduction cascades, and advances in our understanding on how these biological signals are integrated in cancer initiation and progression, have provided new strategies for therapeutic intervention in solid tumors and hematological malignancies. To this end, pharmaceutical efforts have been directed to target different components of the Ras/Raf/MEK and PI3K/PKB pathways. This review article covers recent salient achievements in the identification and development of Raf, MEK, and PI3K inhibitors.

引用

页码：117 / 125

页数：9

共 44 条

[1]

AMIRI P, 2006, P AM ASS CANC RES, V47

[2]

BRIAN P. W., 1957, TRANS BRIT MYCOL SOC, V40, P365

[3]

Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4]

Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].

Davies, SP ;

Reddy, H ;

Caivano, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105

[5]

A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma [J].

Fan, Qi-Wen ;

Cheng, Christine K. ;

Nicolaides, Theodore P. ;

Hackett, Christopher S. ;

Knight, Zachary A. ;

Shokat, Kevan M. ;

Weiss, William A. .

CANCER RESEARCH, 2007, 67 (17) :7960-7965

[6]

FOSTER PG, 2007, EORTC M

[7]

Garcia-Echeverria C, 2007, TOP MED CHEM SER, V1, P169, DOI 10.1007/7355_2006_005

[8]

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity [J].

Garlich, Joseph R. ;

De, Pradip ;

Dey, Nandini ;

Su, Jing Dong ;

Peng, Xiaodong ;

Miller, Antoinette ;

Murali, Ravoori ;

Lu, Yiling ;

Mills, Gordon B. ;

Kundra, Vikas ;

Shu, H-K. ;

Peng, Qiong ;

Durden, Donald L. .

CANCER RESEARCH, 2008, 68 (01) :206-215

[9]

Guilty as charged: B-RAF is a human oncogene [J].

Garnett, MJ ;

Marais, R .

CANCER CELL, 2004, 6 (04) :313-319

[10]

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention [J].

Herrera, R ;

Sebolt-Leopold, JS .

TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S27-S31

← 1 2 3 4 5 →